Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ultralydsbilleddannelse for myofascial smerte

30. september 2026 opdateret af: Ajay Wasan, MD, Msc, University of Pittsburgh

Udvikling og validering af en ikke-invasiv multimodal ultralydsbaseret billeddiagnostisk biomarkør for myofascial smerte

The goal of this observational study is to develop and validate a biomarker for lumbar myofascial pain (MP) based on ultrasound obtained measurements of the lumbar muscles and fascia. The investigators will use advanced machine learning approaches and validation in a randomized controlled trial. The main questions it aims to answer are:

  • Will the deep learning-based marker reliably identify subjects from the 4 different groups: healthy, MP without trigger points, MP with latent trigger points, and MP with active trigger points?
  • Will the deep learning-based marker accurately classify/predict the severity of MP in subjects with cLBP?

Participants in the healthy group will be asked to do the following tasks:

  • Consent/Enrollment
  • Measure Height/Weight
  • Complete Questionnaires on REDCap
  • Participate in Ultrasound Imaging Experiment Sessions

Participants in the chronic low back pain group will be asked to do the following tasks:

  • Consent/Enrollment
  • Complete Questionnaires on REDCap
  • Measure Height/Weight
  • Undergo a Standardized Clinical Exam
  • Participate in Ultrasound Imaging Experiment Sessions

Studieoversigt

Detaljeret beskrivelse

The investigators propose to use multimodal ultrasound imaging to develop and validate a practical and inexpensive biomarker for lumbar myofascial pain, which shows sensitivity to change in relation to treatment. Myofascial pain (MP) is a frequent contributing factor to chronic low back pain (cLBP). It is associated with a range of tissue abnormalities, such as taught muscle bands, trigger points (TPs), and thoracolumbar fascia motion dysfunction, along with poor tissue elasticity. As a result, a composite biomarker for MP related to components of the syndrome is more likely to be plausible biologically, robust, and useful clinically for diagnosis and treatment. The investigators propose to study: 1. The echogenicity of latent and active trigger points, 2. The dynamic spatial-temporal tissue deformation quantified by strain tensors (compression, extension, and shear) in the thoracolumbar fascia and multifidus muscle, 3. The viscoelastic properties of the fascia and muscles measured by ultrasound shear wave elastography. In the R61 Phase (year 1 to 3) the investigators will use deep learning to integrate these measurements into a predictive biomarker and use established validation methods to test its ability to predict MP.

The investigators will determine the sensitivity and specificity of the biomarker to classify the myofascial components of pain, as well as the response to treatment (a diagnostic and predictive marker).

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

124

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Kauffman Medical Building

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The investigators are including healthy normal and cLBP subjects from ages 20 to 70.

Beskrivelse

Inclusion/Exclusion Criteria for Healthy Normals (n=40):

  • No history of chronic low back pain, myofascial pain of the neck or shoulders, or fibromyalgia.
  • Ages 20-70 to be age appropriate to the cLBP subjects. The investigators will recruit 10 subjects per age decile (10 subjects ages 30-39 yrs., etc.).
  • Any clinically unstable systemic illness that is judged to interfere
  • with the trial
  • Non-ambulatory status
  • Not able to complete the questionnaires.

Inclusion Criteria CLBP:

  • Age range 20-70 so that the age distribution is likely to roughly match the healthy normals
  • Predominantly axial cLBP meeting the NIH definition of cLBP (at least 3 months on a daily basis) with a MP component (determined by a standardized clinical exam)
  • Average pain score of > 3/10, with low back pain being the primary pain site
  • cLBP meeting Quebec Task Force Classification System categories I-III (from axial pain only to pain radiating beyond the knee without neurological signs).

Exclusion Criteria CLBP:

  • Back surgery within the past year
  • Active worker's compensation or litigation claims since these patients are more likely to have exaggerated pain behavior
  • New pain treatments within 2 weeks of enrollment
  • Any clinically unstable systemic illness that is judged to interfere with the trial
  • Non-ambulatory status
  • Not able to complete the questionnaires.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Healthy Normals

Participants with no chronic pain over a three-year timeframe.

See above, this is only a phenotyping study but NIH required us to register it as a trial.

MP without TPs

Participants with chronic low back pain who are classified as having myofascial pain and no trigger points.

See above, this is only a phenotyping study but NIH required us to register it as a trial.

MP with latent TPs

Participants with chronic low back pain who are classified as having myofascial pain and latent trigger points.

See above, this is only a phenotyping study but NIH required us to register it as a trial.

MP with active TPs

Participants with chronic low back pain who are classified as having myofascial pain and active trigger points.

See above, this is only a phenotyping study but NIH required us to register it as a trial.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Diagnosis of one of 3 MP-related categories
Tidsramme: Study Visit 1 (week 1)

Participants to be diagnosed as normal, MP with trigger points, or MP with tender points only, as determined by standardized clinical examinations.

Study Visit 1 (week 1)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Presence of Substantial MP
Tidsramme: Study Visit 1 (week 1) - Study Visit 2 (week 2)

The presence of substantial MP (e.g., # active TPs and pressure pain threshold below 6.5 N/cm2) as determined by the standardized clinical examinations.

Study Visit 1 (week 1) - Study Visit 2 (week 2)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Kang Kim, PhD, University of Pittsburgh

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2023

Primær færdiggørelse (Faktiske)

30. september 2026

Studieafslutning (Faktiske)

30. september 2026

Datoer for studieregistrering

Først indsendt

2. juni 2023

Først indsendt, der opfyldte QC-kriterier

29. juni 2023

Først opslået (Faktiske)

3. juli 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STUDY22090014
  • 1R61AT012282-01 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

Depends on the specific request from an outside party

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner